Comprehensive Analysis of Tumor Mutation Burden and Immune Microenvironment in Gastric Cancer

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2021 Jan 25

PMID 33492335

Citations 15

Authors

Jie Yu

Qianyun Zhang

Mengchuan Wang

Sijia Liang

Hongyun Huang

Lang Xie

Chunhui Cui

Jinlong Yu

Affiliations

Soon will be listed here.

Abstract

Tumor mutation burden (TMB) was a promising marker for immunotherapy. We aimed to investigate the prognostic role of TMB and its relationship with immune cells infiltration in gastric cancer (GC). We analyzed the mutation landscape of all GC cases and TMB of each GC patient was calculated and patients were divided into TMB-high and TMB-low group. Differentially expressed genes (DEGs) between the two groups were identified and pathway analysis was performed. The immune cells infiltration in each GC patient was evaluated and Kaplan-Meier analysis was performed to investigate the prognostic role of immune cells infiltration. At last, hub immune genes were identified and a TMB prognostic risk score (TMBPRS) was constructed to predict the survival outcome of GC patients. The relationships between mutants of hub immune genes and immune infiltration level in GC was investigated. We found higher TMB was correlated with better survival outcome and female patients, patients with T1-2 and N0 had higher TMB score. Altogether 816 DEGs were harvested and pathway analysis demonstrated that patients in TMB-high group were associated with neuroactive ligand-receptor interaction, cAMP signaling pathway, calcium signaling pathway. The infiltration of activated CD4+ memory T cells, follicular helper T cells, resting NK cells, M0 and M1 macrophages and neutrophils in TMB-high group were higher compared than that in TMB-low group and high macrophage infiltration was correlated with inferior survival outcome of GC patients. Lastly, the TMBPRS was constructed and GC patients with high TMBPRS had poor prognosis.

Citing Articles

Role of disulfide death in cancer (Review).

Li X, Zhu D Oncol Lett. 2024; 29(1):55.

PMID: 39606569 PMC: 11600708. DOI: 10.3892/ol.2024.14801.

FUT11 expression in gastric cancer: its prognostic significance and role in immune regulation.

Huang Y, Yang X, Wei M, Yang X, Yuan Z, Huang J Discov Oncol. 2024; 15(1):250.

PMID: 38941002 PMC: 11213843. DOI: 10.1007/s12672-024-01120-y.

Attention mechanism based multi-sequence MRI fusion improves prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Zhou X, Yu Y, Feng Y, Ding G, Liu P, Liu L Radiat Oncol. 2023; 18(1):175.

PMID: 37891611 PMC: 10612200. DOI: 10.1186/s13014-023-02352-y.

Prognostic prediction based on histopathologic features of tumor microenvironment in colorectal cancer.

Shi L, Zhang Y, Wang H Front Med (Lausanne). 2023; 10:1154077.

PMID: 37089601 PMC: 10117979. DOI: 10.3389/fmed.2023.1154077.

Potential role of LPAR5 gene in prognosis and immunity of thyroid papillary carcinoma and pan-cancer.

Zhang B, Zhang L, Qi P, Pang R, Wang Z, Liu X Sci Rep. 2023; 13(1):5850.

PMID: 37037831 PMC: 10086052. DOI: 10.1038/s41598-023-32733-y.

References

Wu Y, Xu J, Du C, Wu Y, Xia D, Lv W . The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2019; 9:1161. PMC: 6848266. DOI: 10.3389/fonc.2019.01161. View

Jankovic-Karasoulos T, Bianco-Miotto T, Butler M, Butler L, McNeil C, OToole S . Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology. 2020; 76(7):976-987. DOI: 10.1111/his.14081. View

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O . Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019; 20(2):239-253. DOI: 10.1016/S1470-2045(18)30765-4. View

Brudno J, Lam N, Vanasse D, Shen Y, Rose J, Rossi J . Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020; 26(2):270-280. PMC: 7781235. DOI: 10.1038/s41591-019-0737-3. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View

Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4(1):11-22. DOI: 10.1038/nrc1252. View

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

Horn L, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M . First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. View

10.

Martinez-Romero J, Bueno-Fortes S, Martin-Merino M, Ramirez de Molina A, De Las Rivas J . Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling. BMC Genomics. 2018; 19(Suppl 8):857. PMC: 6288855. DOI: 10.1186/s12864-018-5193-9. View

11.

Hohenberger P, Gretschel S . Gastric cancer. Lancet. 2003; 362(9380):305-15. DOI: 10.1016/s0140-6736(03)13975-x. View

12.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

13.

Karpeh M, Leon L, Klimstra D, Brennan M . Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000; 232(3):362-71. PMC: 1421150. DOI: 10.1097/00000658-200009000-00008. View

14.

Galsky M, Saci A, Szabo P, Han G, Grossfeld G, Collette S . Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res. 2020; 26(19):5120-5128. PMC: 8166422. DOI: 10.1158/1078-0432.CCR-19-4162. View

15.

Fumet J, Truntzer C, Yarchoan M, Ghiringhelli F . Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020; 131:40-50. PMC: 9473693. DOI: 10.1016/j.ejca.2020.02.038. View

16.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

17.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

18.

Dudley J, Lin M, Le D, Eshleman J . Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016; 22(4):813-20. DOI: 10.1158/1078-0432.CCR-15-1678. View

19.

Su C, Fu X, Duan W, Yu P, Zhao Y . High density of CD68+ tumor-associated macrophages predicts a poor prognosis in gastric cancer mediated by IL-6 expression. Oncol Lett. 2018; 15(5):6217-6224. PMC: 5876426. DOI: 10.3892/ol.2018.8119. View

20.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View